CVKD - CIK 0001937993
The table below shows Cadrenal Therapeutics, Inc.'s income statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2008 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of revenue | - | - | $220.09K | - | $220.09K |
| Gross profit | - | - | - | - | - |
| R&D | $4.10M | $4.21M | $4.08M | $392.86K | - |
| SG&A | $9.35M | $6.75M | $3.55M | $2.31M | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Operating income |
| -$13.46M |
| -$10.96M |
| -$7.63M |
| -$2.70M |
| - |
| Income tax | - | - | - | - | - |
| Net income | -$13.24M | -$10.65M | -$8.36M | -$6.71M | - |
| EPS (diluted) | -$6.64 | -$8.73 | -$9.29 | -$0.85 | - |